Cargando…

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is an emerging type of treatment for lung cancer (LC). However, hyperprogressive disease (HPD) has been observed in patients treated with ICIs that lacks a prognostic prediction model. There is an urgent need for a simple and easily implementable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Shuhui, Zhang, Yao, Zhou, Yan, Rong, Wenwen, Wang, Yue, Ling, Xuxinyi, Zhang, Lincheng, Li, Jingwen, Tomita, Yusuke, Watanabe, Satoshi, Nakada, Takeo, Seki, Nobuhiko, Hida, Toyoaki, Dermime, Said, Zhong, Runbo, Zhong, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073744/ https://www.ncbi.nlm.nih.gov/pubmed/35529793 http://dx.doi.org/10.21037/tlcr-22-171

Ejemplares similares

A nomogram model for predicting the risk of checkpoint inhibitor‐related pneumonitis for patients with advanced non‐small‐cell lung cancer
por: Zhang, Yao, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

A Novel Therapeutic Target for Small-Cell Lung Cancer: Tumor-Associated Repair-like Schwann Cells
por: Cao, Shuhui, et al.
Publicado: (2022)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Jingwen, et al.
Publicado: (2021)

Prognostic Implication of the Expression Level of PECAM-1 in Non-small Cell Lung Cancer
por: Cao, Shuhui, et al.
Publicado: (2021)

Mycobacteriumtuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway
por: Cao, Shuhui, et al.
Publicado: (2019)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
por: Wang, Yue, et al.
Publicado: (2020)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
por: Chen, Yan, et al.
Publicado: (2020)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
por: Wang, Mo-Xuan, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
por: Long, Yaping, et al.
Publicado: (2023)

Clinical Guideline-Guided Outcome Consistency for Surgically Resected Stage III Non-Small Cell Lung Cancer: A Retrospective Study
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agqj31la66noidn1lojebf0gdv